FDA Approves Large Studies of Ecstasy to Treat PTSD

ptsd

FDA Approves Large Studies of Ecstasy to Treat PTSD

Large-scale Phase 3 clinical trials of the illegal party drug Ecstasy as a treatment for post-traumatic stress disorder (PTSD) were approved Tuesday by the U.S. Food and Drug Administration.

Some small studies have yielded promising results. If the new trials are successful, Ecstasy (MDMA) could be approved as a prescription drug for PTSD, The New York Times reported.

An FDA spokeswoman declined to comment on the matter, citing rules that forbid providing information about drugs under development.

Click here to Read the full article:  FDA Approves Large Studies of Ecstasy to Treat PTSD